Actineer
- Company typePrivate
- Founded2023
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Actineer firmographics
Firmographics- Name
- Actineer
- Legal name
- Actineer Inc.
- Website
- https://actineer.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Actineer industry classification
Industry- Product category
- Medical Isotope Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)
- akta.pro secondary industries
- Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA), Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE), Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC), Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)
Keywords
Where Actineer is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Actineer business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Infrastructure, Personnel, Supply Chain, Operations
Revenue model
- Actinium-225 Radioisotope Sales: Actineer produces and supplies Actinium-225 (Ac-225) as a starting material/precursor for radiopharmaceutical companies. ITM handles global marketing, sales, and distribution of the final GMP-grade product through its established sales network. Revenue is generated through the sale of Ac-225 radioisotope to pharmaceutical companies developing targeted alpha therapies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Actineer product offering
Product offeringCore offering
Actineer produces and supplies Actinium-225 (Ac-225), a rare alpha-emitting medical radioisotope used as a starting material/precursor for radiopharmaceutical companies developing Targeted Alpha Therapy (TAT) for cancer treatment. The company manufactures Ac-225 via cyclotron-based Radium-226 proton irradiation at Chalk River Laboratories, with GMP-grade processing handled by ITM and global distribution managed through ITM's commercial sales network. Supporting offerings include theranostic application enablement and end-to-end supply chain management for pharmaceutical customers.
Product overview
Actineer is a joint venture between ITM Isotope Technologies Munich SE and Canadian Nuclear Laboratories (CNL) established in October 2023 for the industrial-scale production of Actinium-225 (Ac-225). The company produces and supplies Ac-225, a rare alpha-emitting medical isotope used in Targeted Alpha Therapy (TAT) for cancer treatment. Actineer provides the medical isotope as a starting material for radiopharmaceutical developers, supports clinical trials, and enables the development of innovative targeted alpha therapies. Global sales, marketing, and distribution are managed through ITM's established network, while CNL handles production and raw material supply including exclusive access to Radium-226 (Ra-226). The company also offers theranostic applications combining diagnostic imaging with therapeutic use of Ac-225.
Differentiator
Problem solved
Functional benefit
Products and services
- Actinium-225 (Ac-225) A rare alpha-emitting medical radioisotope produced at industrial scale and supplied as a starting material/precursor for radiopharmaceutical companies developing Targeted Alpha Therapy for cancer treatment. Ac-225 is used in drug development and clinical trials for hard-to-treat tumors.
- Theranostics Service offering enabling the integration of diagnostic imaging and therapeutic applications using Ac-225 and other radiometals for personalized cancer treatment, combining PET/SPECT diagnostics with alpha therapy.
- Ac-225 Supply Chain Management End-to-end supply chain service covering production, processing, quality control, and global distribution of Ac-225 through ITM's established sales network, ensuring on-time in-full delivery to pharmaceutical customers.
Companies that use Actineer
Customer profileSegments2 records
Ideal customer profiles1 record
Actineer technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Actineer partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered supporting, minor and core.
- Sylvia Fedoruk CentresupportingCollaborated with CNL and Actineer on the production of Ac-225. The Fedoruk Centre operates the Saskatchewan Cyclotron Facility owned by the University of Saskatchewan, providing cyclotron access for the first cyclotron irradiation of Radium-226 in Canada to produce Ac-225.
- Advanced Cyclotron Systems Inc. (ACSI)supportingACSI provided the TR-24 Cyclotron and targetry system used by CNL for the first demonstration of Ac-225 production via Ra-226 irradiation in Canada. ACSI is a world leader in cyclotron design and manufacturing with over 30 years of experience.
- Central and Eastern Ontario Isotope Alliance (CEOIA)minorActineer participates in the CEOIA initiative to unite and grow the local isotope community in Ontario, supporting the development of the Canadian isotope ecosystem.
- Canadian Nuclear Isotope Council (CNIC)supportingActineer joined CNIC in December 2023 to support Canada's goal of ensuring reliable supply of medical isotopes and doubling Canada's production of isotopes by 2030. CNIC is a coalition of science, healthcare and nuclear-sector organizations working to maintain Canada's leadership in isotope production.
- ITM Isotope Technologies Munich SE (ITM)coreITM is a founding partner and 50% joint venture owner of Actineer. ITM provides GMP processing of Ac-225 to pharmaceutical grade, global marketing, sales, and distribution through its established sales network. ITM brings radiopharmaceutical development expertise and nearly two decades of radioisotope commercial experience. The joint venture extends ITM's therapeutic portfolio beyond its Lutetium-177 business into targeted alpha therapies.
- Canadian Nuclear Laboratories (CNL)coreCNL is a founding partner and 50% joint venture owner of Actineer. CNL manages and operates the Chalk River Laboratories and provides starting material (Radium-226) for irradiation, manages the interim production process of radiochemical grade Ac-225 supply, and provides access to its nuclear infrastructure. CNL has over 100 years of cumulative experience in nuclear science and isotope production.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
Actineer competitors and assessment
Company assessmentDirect peers
- Nordion (Sotera Health): Canada-headquartered medical isotope producer supplying Cobalt-60, Mo-99/Tc-99m and other reactor-based isotopes globally. Strongly comparable as a Canadian medical isotope supplier and direct geographic/production-method peer to Actineer's CNL-anchored operation at Chalk River.
- ITM Isotope Technologies Munich SE: Founding 50/50 JV partner and exclusive global distribution channel for Actineer. ITM is a Munich-based radiopharmaceutical biotech with ~20 years of radioisotope commercial experience, focused on targeted radionuclide therapies including Lutetium-177 — directly comparable as a GMP-grade medical radioisotope producer and supplier to pharmaceutical developers.
- Lantheus Holdings: Radiopharmaceutical manufacturer with leading diagnostic franchises (e.g., Pylarify, Definity) and growing therapeutic pipeline. Directly comparable as a publicly-traded radiopharmaceutical company with vertically integrated isotope supply and downstream drug development capabilities.
- Advanced Accelerator Applications (Novartis): Novartis subsidiary marketing Lutathera (Lu-177 dotatate) and Pluvicto (Lu-177 vipivotide), the leading commercial targeted radionuclide therapies. Directly comparable as a producer of radioisotope-based cancer therapies and a major consumer of medical radioisotopes.
- Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing targeted theranostic agents (e.g., Illuccix for prostate cancer imaging) and exploring alpha-emitter programs. Comparable as a radiopharmaceutical developer that is one of the target end-customers for Ac-225 supply.
- NTP Radioisotopes (Necsa): South African state-owned medical isotope producer (subsidiary of Necsa) supplying Mo-99 and other isotopes globally via the Safari-1 reactor. Comparable as a national-laboratory-anchored medical isotope producer and direct competitor in the global radioisotope supply market.
Broad incumbents
- Curium Pharma: World's largest nuclear medicine manufacturer, supplying SPECT/PET isotopes and finished radiopharmaceuticals globally. Comparable as a vertically integrated nuclear medicine supplier serving hospitals and pharmaceutical developers, and a potential competitor for radiopharmacy/finished-dose capabilities.
- Bayer (Xofigo / radium-223 program): Pharmaceutical incumbent with Xofigo (radium-223 dichloride), an alpha-emitting therapeutic radiopharmaceutical for prostate cancer. Directly comparable as a developer of alpha-emitter cancer therapies and a long-standing participant in the targeted alpha therapy market that Ac-225 competes with and complements.
- GE HealthCare: Largest commercial radiopharmacy network worldwide, producing and distributing PET and SPECT diagnostic tracers (e.g., Vizamyl, DaTSCAN). Comparable as a major downstream distributor of radioisotope-based products and a broad incumbent in nuclear medicine.
Emerging players
- IBA (Ion Beam Applications): Belgian leader in proton therapy and cyclotron/radioisotope production equipment; supplies cyclotrons and PET isotope production infrastructure used in radiopharmacy. Comparable as an enabling technology supplier for cyclotron-based medical isotope production (relevant to Actineer's TR-24 cyclotron deployment).
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Actineer social profiles
Digital presenceActineer financial estimates
Financial estimateRevenue estimate
Valuation estimate
Actineer leadership team
Management profileNumber of profiles
Profiles2 records
Actineer funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Actineer M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Actineer
What does Actineer do?
Actineer produces and supplies Actinium-225 (Ac-225), a rare alpha-emitting medical radioisotope used as a starting material/precursor for radiopharmaceutical companies developing Targeted Alpha Therapy (TAT) for cancer treatment. The company manufactures Ac-225 via cyclotron-based Radium-226 proton irradiation at Chalk River Laboratories, with GMP-grade processing handled by ITM and global distribution managed through ITM's commercial sales network. Supporting offerings include theranostic application enablement and end-to-end supply chain management for pharmaceutical customers.
Is Actineer a public or private company?
Actineer is a private company. It is classified as corporate owned and is currently operating.
When was Actineer founded?
Actineer was founded in 2023. It employs 11 to 50 people.
Where is Actineer based?
Actineer is headquartered in Toronto, Canada, in the North America region.
How does Actineer make money?
One revenue line is on record: actinium-225 Radioisotope Sales.
Who are Actineer's main competitors?
Direct peers on record are Nordion (Sotera Health), ITM Isotope Technologies Munich SE, Lantheus Holdings, Advanced Accelerator Applications (Novartis), Telix Pharmaceuticals and NTP Radioisotopes (Necsa). Broad incumbents are Curium Pharma, Bayer (Xofigo / radium-223 program) and GE HealthCare. IBA (Ion Beam Applications) is listed as an emerging player.
Does Actineer have an API?
No public API is recorded for Actineer.
What industry is Actineer in?
Actineer's product category is Medical Isotope Manufacturing. Its primary akta.pro industry code is HLAIAGAD, Radioisotope Production (Reactor/Cyclotron/Gamma), with a secondary code of EUAKAIAA, Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.). Its NAICS code is 3254 and its SIC code is 5122.